Lupin Pharmaceuticals Inc. is voluntarily recalling 3,726 bottles of Memantine Hydrochloride Extended-release Capsules (28mg), a medication used to treat symptoms of Alzheimer's disease. The recall was initiated because stability testing showed the drug was not dissolving at the correct rate, which can affect how the medication is released into the body. This recall includes 90-count and 500-count bottles that were distributed nationwide in the United States.
If a medication does not dissolve according to specifications, it may release the active ingredient too slowly or too quickly, potentially reducing the effectiveness of the treatment or causing unexpected side effects.
Healthcare provider consultation and pharmacy refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.